CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 80 enrolled
Drug / intervention
serum magnesium level, FEMgother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05352880
NCT05352880N/ACompleted
CompareCT.gov

Hypomagnesemia and Its Association With Calcineurin Inhibitors Use in Egyptian Renal Transplant Recipients

Alexandria University·interventional·Posted Apr 29, 2022·Updated Dec 14, 2022

In Brief

A clinical study evaluating serum magnesium level, FEMg for Renal Transplantation; Complication. Completed, enrolled 80 participants across 1 site.

Detailed Summary

To assess the prevalence and risk factors of hypomagnesemia and its association with calcineurin inhibitor use among Egyptian renal transplant recipients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Transplantation; Complication
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedApr 29, 2022
Enrollment StartMay 10, 2022
Primary CompletionJul 30, 2022
Study CompletionSep 10, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.2 years ago

Interventions

serum magnesium level, FEMgother

Blood (serum) for: Magnesium (Mg).Urea, creatinine. Calcium (ca), phosphorus (ph).Sodium (Na), potassium (k), chloride (CL).Fasting blood glucose, cholesterol, triglycerides. Intact PTH, 25OH vitamin D.uric acid, albumin. CBC. Trough level of cyclosporine or tacrolimus. ii. Urine for:24 hour urinary: Mg, Ca, Ph, Cl and protein. Spot urine sample to calculate fractional excretion of Mg (FEmg) . Detailed history taking, Thorough Systemic physical examination.